Changes in the structure of primary care delivery, and differences in content of telemedicine visits vs. office-based visits were observed in the USA during the COVID-19 pandemic.
ESC 2020 BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.
ESC 2020 Suspension of ACEi/ARB therapy for 30 days did not impact the number of days alive and out of hospital at 30 days compared to continued use of these medications in COVID-19 patients.
ESC 2020 Although networking opportunities are poor during this year's ESC congress, there are plusses for a digital congress. Prof. Casadei lists some of them.
ESC 2020 During the COVID-19 outbreak, some areas have seen an increase in excess mortality up to 40-50%, not due to COVID-19. Prof. Casadei strongly urgues that in the future, physicians should save lives of patients they know how to save.
Prof. De Boer discusses a recent paper in JAMA Cardiol on cardiac abnormalities detected by cardiovascular MRI in 100 patients who had proven COVID-19 around 2 months ago.
Cardiovascular MRI revealed cardiac involvement in 78% of patients and ongoing myocardial inflammation in 60% of patients in an unselected cohort of 100 patients who recently recovered from COVID-19.
The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has published an expert consensus position paper on conducting clinical trials in HF during and after the COVID-19 pandemic.
A survey conducted by the ESC among cardiologists and CV nurses revealed that 78.8% of responders perceived a decrease in STEMI admissions since the beginning of the COVID-19 outbreak.
Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.
Survival was examined in a cohort of hospitalized COVID-19 patients in New York City, who were divided in those who received anticoagulation during hospital stay and those who did not.
This study showed that 36.3% of patients hospitalized with COVID-19 developed acute kidney injury during hospitalization.